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Abstract The role of endocrine IGF-I for atherosclerosis is
unclear. We determined the importance of circulating, liver-
derived IGF-I for fatty streak formation in mice. Mice with
adult, liver-specific IGF-I inactivation (LI-IGF-I-/- mice,
serum IGF-I reduced by approximately 80 %) and control
mice received an atherogenic (modified Paigen) diet
between 6 and 12 months of age. At study end, Oil Red O
staining of aortic root cryosections showed increased fatty
streak area and lipid deposition in female but not in male LI-
IGF-I-/- mice compared to controls. Mac-2 staining of
aortic root and measurements of CD68 mRNA level in
femoral artery revealed increasedmacrophage accumulation
in proportion to the increased fatty streak area in female LI-
IGF-I-/- mice. Moreover, female LI-IGF-I-/- mice dis-
played increased serum cholesterol and interleukin-6 as well
as increased vascular cell-adhesion molecule 1 (VCAM1)
mRNA levels in the femoral artery and elevated VCAM1
protein expression in the aortic root. Thus, increased diet-
induced fatty streak formation in female LI-IGF-I-/- mice
was associated with increased serum cholesterol and signs of
systemic inflammation, endothelial activation, lipid deposi-
tion, and macrophage infiltration in the vascular wall.
Keywords IGF-I  Liver derived  Fatty streak  Paigen
diet  Inflammation  Endothelial dysfunction
Introduction
Insulin-like growth factor-I (IGF-I) is important for cell
growth and proliferation [1]. Circulating IGF-I, which is
mainly liver-derived [1–3], gradually declines with
increasing age and is dependent on growth hormone (GH)
secretion, food intake, and exercise [1]. Experimental
studies suggest that in addition to regulating postnatal
longitudinal growth, IGF-I maintains brain function, cor-
tical bone mass, cardiovascular performance, and meta-
bolic indices during adulthood [1].
There is increasing clinical evidence that low IGF-I is a
risk factor for cardiovascular disease (CVD) morbidity.
Studies of polymorphisms in the IGF-I gene demonstrate a
link between low serum IGF-I levels and impaired mea-
sures of early atherosclerosis such as increased carotid
intima-media thickness [4, 5]. Hypopituitary patients with
GH deficiency and secondary low circulating IGF-I have
increased CVD morbidity and mortality [6–8]. Epidemio-
logical studies have shown an association between low
serum IGF-I concentrations and increased risk of ischemic
heart disease [9], congestive heart failure [10], and CVD
mortality [11, 12]. A study of elderly Swedish men
demonstrated that not only low but also high serum IGF-I
associates with increased risk of CVD, suggesting a non-
linear U-shaped relation between serum IGF-I and CVD
risk [13]. In chronic heart failure, patients with low serum
IGF-I had increased all-cause mortality compared to those
with higher levels [14]. Notably, GH may exert direct
effects on vascular cells [1, 15], and the importance of
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possible alterations in GH secretion has not been evaluated
in previous studies.
In experimental models, the role of IGF-I in the devel-
opment of atherosclerosis has been controversial. Several
studies have indicated a permissive role of IGF-I in
atherosclerosis [16, 17], particularly by inducing vascular
smoothmuscle cell (VSMC)migration and proliferation [18,
19]. However, the stimulatory effects of IGF-I on VSMCs
might result in stabilization of plaques as supported by
experiments performed both in vitro and in vivo [20]. Fur-
thermore, local smooth muscle-specific IGF-1 overexpres-
sion did not alter total atherosclerotic plaque burden but
resulted in a more stable atherosclerotic lesion phenotype
[21]. Pharmacological administration of IGF-I by systemic
infusions reduced atherosclerosis progression [22, 23], and
genetically modified mice with a 20 % reduction of circu-
lating IGF-I displayed increased atherosclerosis [24].
Finally, pharmacological IGF-I administration may reduce
vascular inflammation [22] by improving nitric oxide (NO)
availability and reducing oxidative stress [22, 25]. In sum-
mary, the role of IGF-I for atherosclerosis development is
still rather unclear and the specific role of liver-derived cir-
culating IGF-I has not yet been evaluated.
In the present study, we determined the role of liver-
derived circulating IGF-I for diet-induced fatty streak for-
mation in adult mice using an inducible mouse model with
selective inactivation of the IGF-I gene in the liver (LI-
IGF-I-/- mice). The LI-IGF-I-/- mice display an
approximately 80 % reduction of serum IGF-I concentra-
tions, whereas the expression of IGF-I is not reduced in
other tissues [1, 2].
Materials and methods
Animals and serum IGF-I
The LI-IGF-I-/- mice on a C57BL/6 background were
generated as described previously [1, 2]. Mice homozygous
for LoxP [26] and hemizygous for Mx-Cre [27] received
three ip injections of polyinosinic-polycytidylic acid (PiPc;
6.25 lg/g body weight; Sigma-Aldrich Corp., Stockholm,
Sweden) at 3 months of age to induce expression of the Cre
protein, thereby inactivating the IGF-I gene in the liver
[27]. PiPc-treated female and male littermates, homozy-
gous for LoxP but lacking Mx-Cre, were used as controls
as previously described [2, 3, 26]. Seven days after the PiPc
injections as well as at the end of the study, serum was
obtained and assayed for IGF-I by a double-antibody IGF-
binding protein-blocked RIA (Mediagnost, Tu¨bingen,
Germany). The mice were housed in a standard animal
facility under controlled temperature (22 C) and pho-
toperiod (12 h of light, 12 h of dark) with free access to
water and food pellets (B&K Universal AB, Sollentuna,
Sweden). Animal care was in accordance with institutional
guidelines. The ethical committee at the University of
Gothenburg approved this study.
Study protocol
All mice (female mice: control, n = 13; LI-IGF-I-/-,
n = 9; male mice: control, n = 16; LI-IGF-I-/-, n = 15)
received an atherogenic diet (modified Paigen) diet
between 6 and 12 months of age. The modified Paigen diet
(diet 12336, Research Diets, Inc., New Brunswick, NJ,
USA) was made of purified components designed to match
the original Paigen diet [28]. The caloric composition was
20 % protein, 35 % fat, and 45 % carbohydrate, and the
diet contained 1.25 % cholesterol and 0.5 % cholate.
Blood was drawn from vena saphena magna before and
2 weeks after the start of the atherogenic diet. After
6 months of the modified Paigen diet (at 12 months of
age), dual-energy X-ray absorptiometry (DEXA) was per-
formed under anesthesia with fentanyl and fluanisone (0.55
and 17.5 mg/kg; Hypnorm, Janssen Pharmaceuticals,
Beerse, Belgium) and midazolam (8.75 mg/kg; Dormicum,
Hoffman-La-Roche Inc., Basel, Switzerland). The circula-
tory system was then perfused with 0.9 % saline (pH 7.4)
under physiological pressure. The aortic root was slowly
frozen in optimum cutting temperature embedding medium
(Sakura Tissue-Tek, Tokyo, Japan). Tissue from the
femoral artery was snap frozen in liquid nitrogen for later
analysis using RT-PCR.
Analysis of serum lipids and cytokines
We used infinity reagents (cholesterol no. TR13421 and
triglycerides no. TR22421; Thermo Fisher Scientific,
Pittsburgh, PA, USA) to analyze total cholesterol and
triglycerides in individual serum samples. Cytokine levels
were measured using a cytokine multiplex panel (mouse
pro inflammatory Vplex from Meso Scale Discovery,
Gaithersburg, MD, USA), including interferon (IFN)-c,
interleukin (IL)-1b, IL-2, IL-5, IL-6, keratinocyte-derived
chemokine (KC/GRO), and tumor necrosis factor (TNF)-a,
in individual serum samples using the electro-chemilumi-
nescence multiplex system Sector 2400 imager (Meso
Scale Discovery).
DEXA
Total body fat and total body lean mass were measured
in vivo at the end of the 6-month modified Paigen diet
using dual-energy X-ray absorptiometry (DEXA; PIXImus,
Lunar Corporation, Madison, MI, USA). The DEXA scans
were from the lower level of the head to the inferior level
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of the first tail vertebra (the maximal scan area of the
DEXA).
Lesion analyses in the aortic root
Serial 10-lm cryosections were cut distally from the aortic
root. The sections immediately after the appearance of the
aortic cusps (i.e., at 0 lm) were stained with Oil Red O
(Sigma-Aldrich, St. Louis, MO, USA). For immunohisto-
chemical staining of macrophages, aortic root cryosections
(40 lm from the aortic cusps) were incubated with rat anti-
mouse Mac-2 antibody (1:1000; Cedarlane, Hornby,
Canada) or isotype control antibody (1:1000; Biolegend,
San Diego, CA, USA) followed by horseradish peroxidase
(HRP)-conjugated goat anti-rat IgG secondary antibody
(1:1000; GE Healthcare, London, UK) and visualized with
DAB substrate kit (Dako, Glostrup, Denmark).
All evaluations of aortic root sections were performed
by a blinded observer, using morphometric analysis (Bio-
Pix Software, Gothenburg, Sweden). Fatty streak area was
defined manually and normalized to the area of the vessel
wall. The areas of Oil Red O staining and Mac-2 staining
were quantified using BioPix Software and normalized to
the vessel wall area or the size of the lesion.
For immunohistochemical staining of vascular cell-ad-
hesion molecule 1 (VCAM1), aortic root cryosections
(80 lm from the aortic cusps) were incubated with anti
VCAM1 antibody (1:50; BD Pharmingen, San Diego, CA,
USA) or isotype control antibody (1:50; BD Bioscience,
Franklin Lakes, NJ, USA) and quantified using software
from Visiopharm (Hoersholm, Denmark).
Triglyceride content in liver
Liver samples were homogenized with isopropanol using
stainless steel beads (5 mm; Qiagen, Hilden, Germany) in a
Tissue-Lyser II (Qiagen), kept for 1 h at 4 C, and cen-
trifuged for 5 min (2500 rpm, 4 C), and the supernatants
were collected. The triglyceride levels in the supernatants
were analyzed using an Infinity reagent (Triglycerides
#TR22421; Thermo Fisher Scientific), and the amount of
triglycerides was normalized to liver sample weights.
Real-time PCR (RT-PCR) analysis
RNA was prepared from the femoral artery using the
RNeasy kit (#74106, Qiagen) according to the manufac-
turer’s instructions. The RNA was reverse transcribed into
cDNA using High-capacity cDNA Reverse transcription kit
(#4368814, Applied Biosystems, Stockholm, Sweden). RT-
PCR analyses were performed using the ABI Prism 7000
Sequence Detection System (PE Applied Biosystems,
Carlsbad, CA, USA). We used pre-designed RT-PCR
assays from Applied Biosystems for the analysis of CD68
(Mm03047340_ml), vascular cell-adhesion molecule 1
(VCAM1; Mm01320970_ml), endothelial NO-synthase
(eNOS; Mm00435217_m1), and IGF-I (Mm00439559_m1)
expression levels (Applied Biosystems). The mRNA
abundance of each gene was adjusted for the expression of
18S rRNA.
Statistical analyses
All descriptive statistical results are presented as the mean
(SEM). All analyses compared two groups (female LI-IGF-
I-/- mice vs. female control mice or male LI-IGF-I-/-
mice vs. male control mice) at one timepoint. The between-
group differences were calculated using unpaired t tests. A
two-tailed p\ 0.05 was considered significant.
Results
Liver-specific inactivation of the IGF-I gene at 3 months of
age reduced serum IGF-I by 81 and 77 % in male and
female mice, respectively [male mice: mean (SEM) 202 (6)
ng/ml in controls vs. 39 (4) ng/ml in LI-IGF-I-/- mice,
p\ 0.001; female mice: 216 (11) ng/ml in controls vs. 50
(5) ng/ml in LI-IGF-I-/- mice, p\ 0.001]. At study end, at
12 months of age, serum IGF-I was reduced by 79 and
72 % in male and female mice, respectively [male mice:
238 (14) ng/ml in controls vs. 51 (5) ng/ml in LI-IGF-I-/-
mice, p\ 0.001; female mice: 246 (17) ng/ml in controls
vs. 68 (11) ng/ml in LI-IGF-I-/- mice, p\ 0.001].
Increased aortic root fatty streak formation
in female, but not male, LI-IGF-I2/2 mice
Fatty streak formation was evaluated in the aortic root.
After 6 months of modified Paigen diet, fatty streak area
and lipid deposition (expressed as lm2 or % of aortic wall
area) were increased in female LI-IGF-I-/- mice compared
to those in controls (Fig. 1a–f). In contrast, there were no
significant differences in these variables in male mice
(Fig. 1a–d). Therefore, since increased fatty streak forma-
tion was present only in female LI-IGF-I-/- mice, we
performed further characterization of vascular lesions only
in female mice.
Increased aortic root macrophage content in female
LI-IGF-I2/2 mice
In the female LI-IGF-I-/- mice, vascular macrophage
infiltration following the diet period was determined using
immunostaining for Mac-2 in the aortic root. The
immunostaining for Mac-2 demonstrated that macrophage
552 Endocrine (2016) 52:550–560
123
area as well as macrophage area normalized to the area of
the aortic wall was increased (Fig. 2a–f), whereas macro-
phage area was not significantly altered when normalized
to the fatty streak area (Fig. 2g). This suggests mainly
unchanged relative macrophage content of fatty streaks in
the female LI-IGF-I-/- mice.
Increased aortic root VCAM1 protein expression
in female LI-IGF-I2/2 mice
As IGF-I affects endothelial function [1], we hypothesized
that deficiency of liver-derived IGF-I may result in signs of
endothelial dysfunction/activation. Immunohistochemistry
analyses revealed increased VCAM1 protein expression in
the aortic root of female LI-IGF-I-/- mice (Fig. 3a–f),
possibly suggesting endothelial dysfunction/activation in
female LI-IGF-I-/- mice.
Measurements of mRNA levels in femoral artery
In the femoral artery of female mice, we performed mRNA
measurements of the macrophage marker CD68 as well as
VCAM1. Furthermore, as IGF-I may improve NO avail-
ability [22, 25], we also measured eNOS mRNA levels.
The measurements demonstrated elevated mRNA expres-
sions of CD68 and VCAM1 in the femoral artery of female
LI-IGF-I-/- mice compared to those of control mice
(Fig. 4a, b). However, eNOS mRNA levels in the femoral
artery were not significantly altered in female LI-IGF-I-/-
mice, to some extent arguing against a NO-mediated
mechanism (Fig. 4c).
We measured IGF-I mRNA levels in the femoral artery
of both female and male LI-IGF-I-/- mice. IGF-I mRNA
levels were increased in female LI-IGF-I-/- mice com-
pared to control mice, whereas there was only a
Fig. 1 Increased fatty streak
formation in aortic wall of
female LI-IGF-I-/- mice. Male
and female LI-IGF-I-/- and
control mice (n = 9–16/group)
received an atherogenic
(modified Paigen) diet from
6 months of age. At the end of
the study (12 months of age),
a fatty streak area and b lipid
deposition were quantified in
Oil Red O-stained aortic root
cryosections. c, d Fatty streak
area and lipid deposition are
given as % of aortic wall area.
One section per mouse was
analyzed at the level of the
aortic cusps. e, f Representative
photomicrographs from female
e control and f LI-IGF-I-/-
mice are shown. Values in a–
d are given as means (SEM).
The analyses of fatty streaks and
lipid deposition were performed
in all mice. p values were
calculated using unpaired t tests.
In e and f, arrows point at fatty
streaks
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non-significant tendency to higher IGF-I mRNA levels in
male LI-IGF-I-/- mice (Fig. 5a).
Hepatic triglyceride content
We measured hepatic triglyceride content as a measure of
liver steatosis. However, hepatic triglyceride content was
similar in both female and male LI-IGF-I-/- mice com-
pared to that in control mice (Fig. 5b).
Systemic inflammation in female LI-IGF-I2/2 mice
To investigate whether the increased fatty streak area in
aortic root of female LI-IGF-I-/- mice was associated with
systemic inflammation, serum levels of cytokines were
measured. Serum IL-6 concentrations were increased both
before and 2 weeks after the start of the atherogenic diet
(Fig. 5c) whereas no significant difference was seen for
serum levels of IFN-c, IL-1b, IL-2, IL-5, KC/GRO, and
TNF-a.
Serum lipids and body composition in female
and male LI-IGF-I2/2 mice
We evaluated serum lipids and body composition in female
as well as in male mice. Both before and 2 weeks after the
start of the modified Paigen diet, serum cholesterol con-
centrations (Fig. 5d) but not triglyceride concentrations
Fig. 2 Increased macrophage content in aortic wall of female LI-
IGF-I-/- mice. Female control (n = 13) and LI-IGF-I-/- (n = 9)
mice received an atherogenic (modified Paigen) diet from 6 to
12 months of age. Macrophage area was quantified using immunos-
taining for Mac-2 in aortic root cryosections (40 lm after the aortic
cusps). a–d Representative photomicrographs from female a, c control
and b, d LI-IGF-I-/- mice are shown. Areas in the rectangles of
a and b are enlarged in c and d, respectively. e, f Quantification of
macrophage area in aortic wall of female mice given as e lm2 and as
f % of aortic wall area. g Macrophage area was not significantly
altered when normalized to the fatty streak area. Values in e–g are
given as means (SEM). p values were calculated using unpaired t tests
554 Endocrine (2016) 52:550–560
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(?16 and ?13 %, both p = N.S.; data not shown) were
increased in female LI-IGF-I-/- mice compared to those in
control mice. In contrast, male LI-IGF-I-/- mice had
similar serum cholesterol concentrations (?8 and ?1 %,
both p = N.S.; data not shown) and triglyceride concen-
trations (data not shown) as control mice. Body weight was
reduced both in female and male LI-IGF-I-/- mice com-
pared to that in control mice, and body composition mea-
surements using DEXA revealed that both the absolute and
relative amounts of total body fat were reduced in female
and male LI-IGF-I-/- mice compared with those in control
mice (Table 1). Thus, obesity is not involved in the
mechanism for increased fatty streak formation in female
LI-IGF-I-/- mice. There was a non-significant trend to
lower lean mass in female LI-IGF-I-/- mice, whereas male
LI-IGF-I-/- mice had significantly lower lean mass than
control mice (Table 1).
Discussion
Circulating IGF-I decreases [1], and the risk of
atherosclerosis increases, with advancing age. Previous
studies have shown conflicting results in terms of the role
of IGF-I in atherosclerosis development [16, 17, 22–24],
and the specific role of liver-derived circulating IGF-I has
not yet been evaluated. In the present study, we demon-
strate that deficiency of liver-derived circulating IGF-I
Fig. 3 Increased VCAM1
protein expression in aortic root
of female LI-IGF-I-/- mice.
Female control (n = 13) and
LI-IGF-I-/- (n = 9) mice
received an atherogenic
(modified Paigen) diet from 6 to
12 months of age. VCAM1
immunostaining was performed




a, c control and b, d LI-IGF-
I-/- mice are shown. Areas in
the rectangles of a and b are
enlarged in c and d,
respectively. e, f Quantification
of VCAM1
immunohistochemistry in aortic
wall of female mice given as
e lm2 and as f % of aortic wall
area. Values in e, f are given as
means (SEM). p values were
calculated using unpaired t tests
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results in increased diet-induced fatty streak formation in
aortic root of female but not male mice. The increased fatty
streak formation in female LI-IGF-I-/- mice was associ-
ated with increased macrophage accumulation (in propor-
tion to the increased fatty streak area) as well as increased
serum levels of cholesterol and IL-6. Furthermore, in
female LI-IGF-I-/- mice, endothelial activation was sug-
gested by increased vascular VCAM1 mRNA levels and
increased VCAM1 protein expression. Therefore, increased
serum cholesterol, systemic inflammation, and endothelial
Fig. 4 Increased mRNA levels of the macrophage marker CD68 and
VCAM1 in femoral artery of female LI-IGF-I-/- mice. Female
control (n = 13) and LI-IGF-I-/- (n = 9) mice received an athero-
genic (modified Paigen) diet from 6 to 12 months of age. At study
end, mRNA levels of a CD68 and b VCAM1 were increased in
femoral artery of female LI-IGF-I-/- mice. In contrast, c eNOS
mRNA levels in femoral artery were unchanged in female LI-IGF-
I-/- mice compared to control mice. Values are given as means
(SEM). p values were calculated using unpaired t tests
Fig. 5 Increased IGF-I mRNA
levels in femoral artery and
elevated serum IL-6 and
cholesterol concentrations in
female LI-IGF-I-/- mice. Male
and female LI-IGF-I-/- and
control mice (n = 9–16/group)
received an atherogenic
(modified Paigen) diet from
6 months of age. a IGF-I
mRNA levels in femoral artery
and b hepatic triglyceride
content at the end of the study in
female and male mice. c IL-6,
and d cholesterol, in serum
before the start of the modified
Paigen diet (baseline) and after
2 weeks of the diet in female
mice. Values are given as means
(SEM). p values were calculated
using unpaired t tests
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dysfunction may contribute to the increased fatty streak
formation in aortic root of female LI-IGF-I-/- mice.
In many models of total or cell-specific knockout of
IGF-I, the role of IGF-I in adult life has been difficult to
evaluate due to the possible effect of the absence of IGF-I
activity during pre- and postnatal development [1].
Importantly, in this study, the deficiency of endocrine,
liver-derived IGF-I was induced at 3 months of age. Con-
sequently, the mice developed normally but then under-
went a maintained, selective inactivation of IGF-I in
hepatocytes resulting in a 75–80 % reduction of serum
IGF-I [2, 29–40]. Therefore, our data clearly show that
circulating IGF-I has a vasculoprotective role in female
mice, which is independent of any developmental effects.
Furthermore, our results extends previous findings of
reduced atherosclerosis following pharmacological admin-
istration of IGF-I using systemic infusions [22, 23], and
increased atherosclerosis in genetically modified mice with
a 20 % reduction of circulating IGF-I [24]. However,
limitations of the present study include that apolipoprotein
E-deficient mice or LDL receptor-deficient mice were not
used and that, e.g., the rate of cholesterol clearance from
the arterial wall as well as oxidation of cholesterol were not
determined. Furthermore, other limitations are that infil-
tration of inflammatory cells in liver was not measured and
that only one marker (VCAM1) was used to evaluate
endothelial function.
We did not measure insulin sensitivity in the present
study, but several previous studies have shown that defi-
ciency of liver-derived IGF-I in mice is characterized by
insulin resistance [29, 41, 42]. The LI-IGF-I-/- mice have
compensated insulin resistance with unchanged blood
glucose level [29], reduced cardiac output [32], increased
systolic blood pressure associated with increased peripheral
vascular resistance [32], and signs of endothelial dysfunc-
tion associated with impaired vasorelaxation of resistance
vessels [32]. In the present study, mRNA levels of eNOS in
the femoral artery of female LI-IGF-I-/- mice were not
significantly affected. This concurs with our previous
finding, which included administration of the NO-synthase
inhibitor L-NAME as well as measurements of plasma
nitrate, that alterations in vascular tone in LI-IGF-I-/-
mice are not primarily regulated by NO [32]. In a study of
mice receiving pharmacological IGF-I administration by
systemic infusions, the anti-atherosclerotic effect of IGF-I
was NO-independent [23]. However, eNOS activity has not
been evaluated in the LI-IGF-I-/- mice. Therefore, we
cannot exclude that a NO-mediated mechanism might be
involved in the increased fatty streak formation in the LI-
IGF-I-/- mice.
Both IGF-I and the IGF-I receptors are expressed in the
vasculature [1], indicating that IGF-I may exert its effects in
an autocrine/paracrine manner. However, as observed in LI-
IGF-I-/- mice, IGF-I also has important endocrine actions.
We previously hypothesized that the conflicting results of
previous studies [16, 17, 22–24] could be due to different
effects of circulating IGF-I versus locally produced IGF-I in
the vasculature. Our present data suggest that liver-derived
endocrine IGF-I may protect against diet-induced fatty
streak formation in aortic root by improving lipid levels and
endothelial function. In contrast, we previously speculated
that locally produced IGF-I could potentially increase
atherosclerosis by inducing VSMC migration and prolifer-
ation [1]. However, the in vitro and in vivo study by von der
Thu¨sen suggested that VSMC-mediated effects of IGF-I
could stabilize atheromatous plaques [20]. Furthermore,
smooth muscle-specific IGF-1 overexpression did not alter
total atherosclerotic plaque burden but resulted in a more
stable atherosclerotic lesion phenotype [21]. Therefore, our
present hypothesis is that liver-derived circulating IGF-I
protects against atherosclerosis, whereas locally derived
IGF-I in the arterial wall likely is relatively neutral in terms
of atherosclerotic lesion size.
At 6 months of age, serum cholesterol was increased in
female but not in male LI-IGF-I-/- mice both before and
2 weeks after the start of the modified Paigen diet. It is less
Table 1 Body composition of
female and male LI-IGF-I-/-
mice
Female mice Male mice
Control LI-IGF-I-/- Control LI-IGF-I-/-
Body weight (g) 33.2 (1.4) 28.2 (2.0)* 41.0 (2.8) 31.3 (1.1)**
DEXA
Body fat (g) 12.6 (1.2) 8.1 (1.5)* 15.0 (2.0) 8.8 (0.9)*
Body fat (%) 37.7 (2.5) 29.3 (3.4)* 36.3 (2.7) 29.0 (2.1)*
Lean mass (g) 18.8 (0.4) 18.0 (0.6) 23.3 (0.7) 20.7 (0.5)**
Male and female LI-IGF-I-/- and control mice (n = 9–16/group) received an atherogenic (modified
Paigen) diet from 6 months of age. At the end of the study (at 12 months of age), in vivo measurements
using DEXA were performed. The DEXA scans were from the lower level of the head to the inferior level
of the first tail vertebra (the maximal scan area of the DEXA). Values are given as means (SEM)
* p\ 0.05; ** p\ 0.01 vs. control mice using unpaired t tests
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likely that this relatively subtle gender difference was of
major importance for the sexual dimorphism in fatty streak
formation. In previous studies, both male and female
4-month-old LI-IGF-I-/- mice had increased serum
cholesterol compared to controls [29], whereas tail-cuff
systolic blood pressure was more markedly increased in
female LI-IGF-I-/- mice than that in male LI-IGF-I-/-
mice compared to that in control mice [32]. Therefore,
more severely impaired systolic blood pressure in female
LI-IGF-I-/- mice could be one mechanism underlying the
gender difference in diet-induced fatty streak formation. In
the present study, IGF-I mRNA levels in the femoral artery
were increased in female IGF-I-/- mice, whereas there was
only a non-significant tendency to an increase in male IGF-
I-/- mice. The importance of this finding for the observed
gender differences is not clear since recent studies suggest
that IGF-I in the arterial wall stabilizes atherosclerotic
lesions without any effect on total atherosclerotic plaque
burden [20, 21]. In summary, the mechanisms underlying
the gender differences observed in the present study are not
fully clear and further mechanistic studies are needed. Such
studies could include estradiol or testosterone treatment of
ovariectomized mice to evaluate the role of estrogen.
It has previously not been studied in detail whether the
effects of IGF-I on the vasculature are sexually dimorphic
in mice, but some previous studies in mice have suggested
that the importance of IGF-I for life span regulation is
gender specific [38, 43]. In humans, adult hypopituitary
patients with severe GH deficiency and secondary low IGF-
I display subclinical inflammation [44], disturbed serum
lipid pattern [45], insulin resistance [46], elevated diastolic
blood pressure [47], and premature atherosclerosis indi-
cated by increased carotid intima-media thickness [48, 49].
There is some evidence that women might have more
severe consequences of the hypopituitary disease than men
both in terms of cardiovascular risk factors [50] and CVD
morbidity and mortality [8, 51]. However, the results of
epidemiological studies have not suggested any clear
gender differences and the importance of possible direct
effects of GH on vascular cells have not been evaluated in
detail in previous studies. Therefore, our results are in line
with some but not all previous findings across species that
the consequences of low circulating IGF-I might differ
between males and females in terms of several endpoints
including atherosclerosis progression.
In the present study, female LI-IGF-I-/- mice displayed
increased serum cholesterol. As IGF-I exerts anti-inflam-
matory effects, we also measured serum cytokine levels in
female mice. Serum IL-6 concentrations were increased in
female LI-IGF-I-/- mice both before and 2 weeks after the
start of the atherogenic diet. This is in line with the pre-
vious findings in hypopituitary patients [44] and in non-
diabetic subjects [52] that IGF-I is a regulator of circulating
IL-6. Thus, increased systemic inflammation might con-
tribute to increased fatty streak formation in aortic wall of
female LI-IGF-I-/- mice although this requires confirma-
tion in further studies. In addition, we previously showed
elevated systolic blood pressure and impaired vasorelax-
ation in LI-IGF-I-/- mice [32]. Therefore, the increased
fatty streak formation in aortic wall of female LI-IGF-I-/-
mice is associated with increased serum cholesterol, sys-
temic inflammation, and signs of endothelial activation.
Body weight and percentage body fat were reduced in
female as well as in male LI-IGF-I-/- mice, excluding a
role of obesity in the increased fatty streak formation in
aortic wall of female LI-IGF-I-/- mice. However, these
findings are in line with previous observations that defi-
ciency of liver-derived IGF-I results in a gradual reduction
of body fat over time [1, 29, 53]. In LI-IGF-I-/- mice, GH
levels are compensatory increased [1, 2, 30], and it is most
likely that reduced body fat in LI-IGF-I-/- mice is caused
by the increased GH secretion [1]. The extent to which a
compensatory increase in GH levels also could affect
atherosclerosis progression is not fully clear. Transgenic
mice overexpressing GH have a 50- to 100-fold increase in
circulating GH levels [15] and increased atherosclerosis
[54], but there are no indications that a moderate increase
in GH secretion would be atherogenic in mice.
In conclusion, we demonstrate that female mice with
deficiency of liver-derived IGF-I display increased diet-
induced fatty streak formation in the aortic root. This was
associated with increased serum cholesterol and increased
systemic inflammation as well as signs of endothelial
activation, lipid deposition, and macrophage infiltration in
the vascular wall.
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